Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Inovio Pharma (INO)

Inovio Pharma (INO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Inovio Pharma 660 W. GERMANTOWN PIKE SUITE 110 PLYMOUTH MEETING PA 19462 USA

P: 267-440-4200 F: 267-440-4242

Description:

Inovio Pharmaceuticals, Inc., formerly known as Inovio Biomedical Corporation, is engaged in the discovery, development, and delivery of a new generation of vaccines, called DNA vaccines, focused on cancers and infectious diseases. The Company's electroporation DNA delivery technology uses brief, controlled electrical pulses to increase cellular DNA vaccine uptake. Inovio's clinical programs include human papillomavirus (HPV)/cervical cancer (therapeutic), avian influenza (preventative), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) vaccines. It is advancing preclinical research for a universal seasonal/pandemic influenza vaccine. The Company's partners and collaborators include University of Pennsylvania, National Microbiology Laboratory of the Public Health Agency of Canada, NIAID, Merck, ChronTech, University of Southampton, and HIV Vaccines Trial Network. Inovio Pharmaceuticals, Inc. is headquartered in Blue Bell, Pennsylvania.

Key Statistics

Overview:

Market Capitalization, $K 3,391,159
Shares Outstanding, K 158,096
Annual Sales, $ 4,110 K
Annual Net Income, $ -119,360 K
Last Quarter Sales, $ 1,330 K
Last Quarter Net Income, $ -32,540 K
60-Month Beta 1.47
% of Insider Shareholders 4.00%
% of Institutional Shareholders 27.82%
Float, K 151,772
% Float 96.00%

Growth:

1-Year Return 618.59%
3-Year Return 172.21%
5-Year Return 187.53%
5-Year Revenue Growth -60.71%
5-Year Earnings Growth -81.25%
5-Year Dividend Growth 0.00%

Per-Share Information:

Next Earnings Date 08/13/20
Earnings Per Share ttm -1.15
EPS Growth vs. Prev Qtr 18.75%
EPS Growth vs. Prev Year 13.33%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00
Most Recent Split 1-4 on 06/06/14

INO Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward -5.73
Price/Earnings to Growth N/A
Return-on-Equity % -166.85%
Return-on-Assets % -59.66%
Profit Margin % -2,904.14
Net Margin % -141.23
Debt/Equity 0.51
Price/Sales 758.57
Price/Cash Flow N/A
Price/Book 16.66
Book Value/Share 1.29
Interest Coverage -14.20
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar